The news: The National Institutes of Health (NIH) plans to start a public-private cancer vaccine program in December, focusing on pancreatic, liver, and colorectal cancers along with certain pediatric tumors, per the New York Times. The collaboration will bring together drugmakers, researchers, advocacy groups, and philanthropic organizations to develop and test personalized cancer vaccines.

Why it matters: The initiative adds significant government support to the growing field of cancer vaccine research, but recent trial results highlight both the promise and the setbacks shaping the field.

In the strongest supporting evidence to date, Merck and Moderna said in August that their personalized mRNA cancer vaccine, used alongside Keytruda, slowed the return and spread of melanoma in a Phase 3 trial. But that same month, Roche and BioNTech ended a midstage colon cancer vaccine trial, though they continue to test the treatment across other cancer types and drug combinations. Meanwhile, biotech MimiVax this week reported improved median overall survival in patients with newly diagnosed glioblastoma despite missing the trial's primary endpoints. They plan to continue into further clinical trials.

Implications for pharma companies: Progress in personalized cancer vaccines represents more than a clinical milestone for pharma—it opens a lucrative expansion route within the industry’s largest treatment category. Global spending on cancer medicines is expected to reach $441 billion by 2029, per IQVIA.

Capturing this market hinges on trial execution and scale. Participating in the NIH initiative—especially by tapping its Phase 2 national clinical trial network—could help drugmakers advance their own cancer vaccine programs by pooling research resources, accelerate testing, reduce R&D costs, and generate stronger evidence to support FDA approval.

This content is part of EMARKETER’s subscription Briefings, where we pair daily updates with data and analysis from forecasts and research reports. Our Briefings prepare you to start your day informed, to provide critical insights in an important meeting, and to understand the context of what’s happening in your industry. Not a subscriber? Click here to get a demo of our full platform and coverage.